nach oben

Neurotherapeutics

Erschienen in:

01.10.2020 | Review

Surgical Treatment of Parkinson’s Disease: Devices and Lesion Approaches

verfasst von: Vibhash D. Sharma, Margi Patel, Svjetlana Miocinovic

Erschienen in: Neurotherapeutics | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Surgical treatments have transformed the management of Parkinson’s disease (PD). Therapeutic options available for the management of PD motor complications include deep brain stimulation (DBS), ablative or lesioning procedures (pallidotomy, thalamotomy, subthalamotomy), and dopaminergic medication infusion devices. The decision to pursue these advanced treatment options is typically done by a multidisciplinary team by considering factors such as the patient’s clinical characteristics, efficacy, ease of use, and risks of therapy with a goal to improve PD symptoms and quality of life. DBS has become the most widely used surgical therapy, although there is a re-emergence of interest in ablative procedures with the introduction of MR-guided focused ultrasound. In this article, we review DBS and lesioning procedures for PD, including indications, selection process, and management strategies.

Nur mit Berechtigung zugänglich

Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic apparatus for operations on the human brain. Science 1947;106(2754):349-350.PubMedCrossRef

Spiegel EA, Wycis HT. Stereoencephalotomy: Methods and stereotaxic atlas of the human brain: Grune & Stratton; 1952.

Hassler R. Indikationen und Lokalizationsmethode der gezielten Hirnoperationen. Nervenarzt 1954;25:441-447.PubMed

Cooper IS. Ligation of the anterior choroidal artery for involuntary movements-parkinsonism. Psychiatr Q 1953;27(1-4):317-319.PubMedCrossRef

Narabayashi H, Okuma T. Procaine-oil blocking of the globus pallidus for the treatment of rigidity and tremor of parkinsonism (preliminary report). Proc Jpn Acad 1953;29(3):134-137.CrossRef

Gildenberg PL. Evolution of neuromodulation. Stereotact Funct Neurosurg 2005;83(2-3):71-79.PubMedCrossRef

Albe Fessard D, Arfel G, Guiot G, Derome P, Dela H, Korn H, et al. [CHARACTERISTIC ELECTRIC ACTIVITIES OF SOME CEREBRAL STRUCTURES IN MAN]. Ann Chir. 1963;17:1185-214.

Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276(7):374-379.PubMedCrossRef

Narabayashi H, Yokochi F, Nakajima Y. Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 1984;47(8):831-839.PubMedPubMedCentralCrossRef

10.

Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992;76(1):53-61.PubMedCrossRef

11.

DeLong MR, Crutcher MD, Georgopoulos AP. Primate globus pallidus and subthalamic nucleus: functional organization. J Neurophysiol 1985;53(2):530-543.PubMedCrossRef

12.

Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12(10):366-375.PubMedCrossRef

13.

Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987;50(1-6):344-346.PubMed

14.

Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996;84(2):203-214.PubMedCrossRef

15.

Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997;42(3):292-299.PubMedCrossRef

16.

Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992;76(1):53-61.PubMedCrossRef

17.

Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249(4975):1436-1438.PubMedCrossRef

18.

Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 1994;35(6):1126-1129; discussion 9-30.PubMedCrossRef

19.

Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345(8942):91-95.PubMedCrossRef

20.

Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005;62(8):1250-5.PubMedCrossRef

21.

Lang AE, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002;17(S3):S94-S101.PubMedCrossRef

22.

Welter M, Houeto J, Tezenas du Montcel S et al. Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain 2002;125(3):575-583.PubMedCrossRef

23.

Charles PD, Van Blercom N, Krack P, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002;59(6):932-934.PubMedCrossRef

24.

Derost PP, Ouchchane L, Morand D, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 2007;68(17):1345-1355.PubMedCrossRef

25.

Russmann H, Ghika J, Villemure JG, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004;63(10):1952-1954.PubMedCrossRef

26.

Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301(1):63-73.PubMedPubMedCentralCrossRef

27.

Mathkour M, Garces J, Scullen T, et al. Short- and long-term outcomes of deep brain stimulation in patients 70 years and older with Parkinson disease. World Neurosurg 2017;97:247-252.PubMedCrossRef

28.

Sharma VD, Lyons KE, Nazzaro JM, Pahwa R. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75years of age. J Neurol Sci 2019;399:57-60.PubMedCrossRef

29.

Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 2013;368(7):610-622.PubMedCrossRef

30.

Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005;62(4):554-60.PubMedCrossRef

31.

Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial Ann Neurol 2009;65(5):586-595.PubMedPubMedCentralCrossRef

32.

Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 2012;79(1):55-65.PubMedPubMedCentralCrossRef

33.

Odekerken VJ, Boel JA, Schmand BA, et al. GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology 2016;86(8):755-761.PubMedCrossRef

34.

Mansouri A, Taslimi S, Badhiwala JH, et al. Deep brain stimulation for Parkinson’s disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg 2018;128(4):1199-1213.PubMedCrossRef

35.

Wong JK, Cauraugh JH, Ho KWD, et al. STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2019;58:56-62.PubMedCrossRef

36.

Follett KA. Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurg Focus 2004;17(1):E3.PubMedCrossRef

37.

Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 2010;362(22):2077-2091.PubMedCrossRef

38.

Mei S, Eisinger RS, Hu W, Tsuboi T, Foote KD, Hass CJ, et al. Three-Year Gait and Axial Outcomes of Bilateral STN and GPi Parkinson's Disease Deep Brain Stimulation. Front Hum Neurosci. 2020;14:1.

39.

George RS, Nutt J, Burchiel K, Horak F. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010;75(14):1292-1299.CrossRef

40.

Boel JA, Odekerken VJ, Schmand BA, et al. Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson’s disease. Parkinsonism Relat Disord 2016;33:90-95.PubMedCrossRef

41.

Wang JW, Zhang YQ, Zhang XH, et al. Psychiatric effects of STN versus GPi deep brain stimulation in Parkinson's disease: a meta-analysis of randomized controlled trials. PLoS One 2016;11(6):e0156721.PubMedPubMedCentralCrossRef

42.

Lyons K, Koller W, Wilkinson S, Pahwa R. Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor. J Neurol Neurosurg Psychiatry 2001;71(5):682-684.PubMedPubMedCentralCrossRef

43.

Cury RG, Fraix V, Castrioto A, et al. Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. Neurology 2017;89(13):1416-1423.PubMedCrossRef

44.

Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. Neuroreport 2005;16(17):1883-1887.PubMedCrossRef

45.

Ferraye M, Debû B, Fraix V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain 2010;133(1):205-214.PubMedCrossRef

46.

Mestre TA, Sidiropoulos C, Hamani C, et al. Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson’s disease. Mov Disord 2016;31(10):1570-4.PubMedCrossRef

47.

Welter M-L, Demain A, Ewenczyk C, et al. PPNa-DBS for gait and balance disorders in Parkinson’s disease: a double-blind, randomised study. J Neurol 2015;262(6):1515-1525.PubMedCrossRef

48.

Plaha P, Ben-Shlomo Y, Patel NK, Gill SS. Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain 2006;129(Pt 7):1732-1747.PubMedCrossRef

49.

Kitagawa M, Murata J-i, Uesugi H, et al. Two-year follow-up of chronic stimulation of the posterior subthalamic white matter for tremor-dominant Parkinson’s disease. Neurosurgery 2005;56(2):281-289.PubMedCrossRef

50.

Blomstedt P, Persson RS, Hariz G-M, et al. Deep brain stimulation in the caudal zona incerta versus best medical treatment in patients with Parkinson’s disease: a randomised blinded evaluation. J Neurol Neurosurg Psychiatry 2018;89(7):710-716.PubMedCrossRef

51.

Peppe A, Gasbarra A, Stefani A, et al. Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson’s disease? Parkinsonism Relat Disord 2008;14(6):501-504.PubMedCrossRef

52.

Sharma VD, Mewes K, Wichmann T, Buetefisch C, Willie JT, DeLong M. Deep brain stimulation of the centromedian thalamic nucleus for essential tremor: a case report. Acta Neurochir 2017;159(5):789-793.PubMedCrossRef

53.

Alberts JL, Hass CJ, Vitek JL, Okun MS. Are two leads always better than one: an emerging case for unilateral subthalamic deep brain stimulation in Parkinson's disease. Exp Neurol 2008;214(1):1-5.PubMedPubMedCentralCrossRef

54.

Petraglia FW, 3rd, Farber SH, Han JL, et al. Comparison of bilateral vs. staged unilateral deep brain stimulation (DBS) in Parkinson’s disease in patients under 70 years of age. Neuromodulation 2016;19(1):31-37.PubMedCrossRef

55.

Walker HC, Watts RL, Guthrie S, Wang D, Guthrie BL. Bilateral effects of unilateral subthalamic deep brain stimulation on Parkinson’s disease at 1 year. Neurosurgery 2009;65(2):302-310.PubMedCrossRef

56.

Slowinski JL, Putzke JD, Uitti RJ, et al. Unilateral deep brain stimulation of the subthalamic nucleus for Parkinson disease. J Neurosurg 2007;106(4):626-632.PubMedCrossRef

57.

Taba HA, Wu SS, Foote KD, et al. A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort. J Neurosurg 2010;113(6):1224-1229.PubMedCrossRef

58.

Zahodne LB, Okun MS, Foote KD, et al. Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. J Neurol 2009;256(8):1321-1329.PubMedPubMedCentralCrossRef

59.

Steigerwald F, Matthies C, Volkmann J. Directional deep brain stimulation. Neurotherapeutics 2019;16(1):100-104.PubMedCrossRef

60.

Timmermann L, Jain R, Chen L, et al. Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson's disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study. Lancet Neurol 2015;14(7):693-701.PubMedCrossRef

61.

Dembek TA, Reker P, Visser-Vandewalle V, et al. Directional DBS increases side-effect thresholds-a prospective, double-blind trial. Mov Disord 2017;32(10):1380-1388.PubMedCrossRef

62.

Rebelo P, Green AL, Aziz TZ, et al. Thalamic directional deep brain stimulation for tremor: spend less, get more. Brain Stimul 2018;11(3):600-606.PubMedCrossRef

63.

Barbe MT, Maarouf M, Alesch F, Timmermann L. Multiple source current steering–a novel deep brain stimulation concept for customized programming in a Parkinson's disease patient. Parkinsonism Relat Disord 2014;20(4):471-473.PubMedCrossRef

64.

Ten Brinke TR, Odekerken VJJ, Dijk JM, van den Munckhof P, Schuurman PR, de Bie RMA. Directional deep brain stimulation: first experiences in centers across the globe. Brain Stimul 2018;11(4):949-950.PubMedCrossRef

65.

Machado A, Rezai AR, Kopell BH, Gross RE, Sharan AD, Benabid AL. Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management. Mov Disord 2006;21 Suppl 14:S247-S258.PubMedCrossRef

66.

Gross RE, Krack P, Rodriguez-Oroz MC, Rezai AR, Benabid AL. Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov Disord 2006;21 Suppl 14:S259-S283.PubMedCrossRef

67.

Holloway K, Docef A. A quantitative assessment of the accuracy and reliability of O-arm images for deep brain stimulation surgery. Neurosurgery 2013;72(1 Suppl Operative):47-57.PubMed

68.

Burchiel KJ, McCartney S, Lee A, Raslan AM. Accuracy of deep brain stimulation electrode placement using intraoperative computed tomography without microelectrode recording. J Neurosurg 2013;119(2):301-306.PubMedCrossRef

69.

Ostrem JL, Ziman N, Galifianakis NB, et al. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson’s disease. J Neurosurg 2016;124(4):908-916.PubMedCrossRef

70.

Aziz TZ, Hariz M. To sleep or not to sleep during deep brain stimulation surgery for Parkinson disease? Neurology 2017;89(19):1938-1939.PubMedCrossRef

71.

Lozano CS, Ranjan M, Boutet A, Xu DS, Kucharczyk W, Fasano A, Lozano AM. Imaging alone versus microelectrode recording-guided targeting of the STN in patients with Parkinson's disease. J Neurosurg. 2018 Jul 1:1-6. https://doi.org/10.3171/2018.2.JNS172186 Epub ahead of print. PMID: 30074454.

72.

Geraedts VJ, van Ham RAP, Marinus J, et al. Intraoperative test stimulation of the subthalamic nucleus aids postoperative programming of chronic stimulation settings in Parkinson’s disease. Parkinsonism Relat Disord 2019;65:62-66.PubMedCrossRef

73.

Zrinzo L, Foltynie T, Limousin P, Hariz MI. Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg 2012;116(1):84-94.PubMedCrossRef

74.

Brodsky MA, Anderson S, Murchison C, et al. Clinical outcomes of asleep vs awake deep brain stimulation for Parkinson disease. Neurology 2017;89(19):1944-1950.PubMedCrossRef

75.

Bezchlibnyk YB, Sharma VD, Naik KB, Isbaine F, Gale JT, Cheng J, Triche SD, Miocinovic S, Buetefisch CM, Willie JT, Boulis NM, Factor SA, Wichmann T, DeLong MR, Gross RE. Clinical outcomes of globus pallidus deep brain stimulation for Parkinson disease: a comparison of intraoperative MRI- and MER-guided lead placement. J Neurosurg. 2020 Mar 6:1-11. https://doi.org/10.3171/2019.12.JNS192010. Epub ahead of print. PMID: 32114534.

76.

Ho AL, Ali R, Connolly ID, et al. Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry 2018;89(7):687-691.PubMedCrossRef

77.

Hell F, Palleis C, Mehrkens JH, Koeglsperger T, Bötzel K. Deep Brain Stimulation Programming 2.0: future perspectives for target identification and adaptive closed loop stimulation. Front Neurol 2019;10:314.PubMedPubMedCentralCrossRef

78.

Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006;355(9):896-908.PubMedCrossRef

79.

Schüpbach W, Maltete D, Houeto J, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007;68(4):267-271.PubMedCrossRef

80.

Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 2008;7(7):605-614.PubMedCrossRef

81.

Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurol 2012;11(2):140-149.PubMedCrossRef

82.

Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9(6):581-591.PubMedPubMedCentralCrossRef

83.

Hitti FL, Ramayya AG, McShane BJ, Yang AI, Vaughan KA, Baltuch GH. Long-term outcomes following deep brain stimulation for Parkinson's disease. J Neurosurg. 2019 Jan 18:1-6. https://doi.org/10.3171/2018.8.JNS182081. Epub ahead of print. PMID: 30660117.

84.

Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68(12):1550-1556.PubMedCrossRef

85.

Seijo FJ, Alvarez-Vega MA, Gutierrez JC, Fdez-Glez F, Lozano B. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochir. 2007;149(9):867-875; discussion 76.PubMedCrossRef

86.

Videnovic A, Metman LV. Deep brain stimulation for Parkinson’s disease: prevalence of adverse events and need for standardized reporting. Mov Disord 2008;23(3):343-349.PubMedCrossRef

87.

Fenoy AJ, Simpson RK, Jr. Risks of common complications in deep brain stimulation surgery: management and avoidance. J Neurosurg 2014;120(1):132-139.PubMedCrossRef

88.

Goodman RR, Kim B, McClelland S, 3rd, et al. Operative techniques and morbidity with subthalamic nucleus deep brain stimulation in 100 consecutive patients with advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006;77(1):12-17.PubMedPubMedCentralCrossRef

89.

Sharma VD, Lyons KE, Nazzaro JM, Pahwa R. Does post-operative symptomatic lead edema associated with subthalamic DBS implantation impact long-term clinical outcomes? J Neurol Sci 2020;410:116647.PubMedCrossRef

90.

Paim Strapasson AC, Martins Antunes AC, Petry Oppitz P, Dalsin M, de Mello Rieder CR. Postoperative confusion in patients with Parkinson disease undergoing deep brain stimulation of the subthalamic nucleus. World Neurosurg 2019;125:e966-e971.PubMedCrossRef

91.

Sharma VD, Bona AR, Mantovani A, et al. Cystic lesions as a rare complication of deep brain stimulation. Mov Disord Clin Pract 2016;3(1):87-90.PubMedCrossRef

92.

Waldvogel D, Baumann-Vogel H, Stieglitz L, Hanggi-Schickli R, Baumann CR. Beware of deep water after subthalamic deep brain stimulation. Neurology 2020;94(1):39-41.PubMedCrossRef

93.

Rolston JD, Englot DJ, Starr PA, Larson PS. An unexpectedly high rate of revisions and removals in deep brain stimulation surgery: analysis of multiple databases. Parkinsonism Relat Disord 2016;33:72-77.PubMedPubMedCentralCrossRef

94.

Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 2008;131(Pt 10):2720-2728.PubMedPubMedCentralCrossRef

95.

Weintraub D, Duda JE, Carlson K, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013;84(10):1113-1118.PubMedCrossRef

96.

Miocinovic S, Somayajula S, Chitnis S, Vitek JL. History, applications, and mechanisms of deep brain stimulation. JAMA Neurol 2013;70(2):163-171.PubMedCrossRef

97.

Dostrovsky JO, Levy R, Wu JP, Hutchison WD, Tasker RR, Lozano AM. Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J Neurophysiol 2000;84(1):570-574.PubMedCrossRef

98.

Welter ML, Houeto JL, Bonnet AM, et al. Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients. Arch Neurol 2004;61(1):89-96.PubMedCrossRef

99.

Hashimoto T, Elder CM, Okun MS, Patrick SK, Vitek JL. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J Neurosci 2003;23(5):1916-1923.PubMedPubMedCentralCrossRef

100.

McIntyre CC, Grill WM, Sherman DL, Thakor NV. Cellular effects of deep brain stimulation: model-based analysis of activation and inhibition. J Neurophysiol 2004;91(4):1457-1469.PubMedCrossRef

101.

Grill WM, Snyder AN, Miocinovic S. Deep brain stimulation creates an informational lesion of the stimulated nucleus. Neuroreport 2004;15(7):1137-1140.PubMedCrossRef

102.

Kuhn AA, Kempf F, Brucke C, et al. High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance. J Neurosci 2008;28(24):6165-6173.PubMedPubMedCentralCrossRef

103.

de Hemptinne C, Swann NC, Ostrem JL, et al. Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson’s disease. Nat Neurosci 2015;18(5):779-786.PubMedPubMedCentralCrossRef

104.

Herrington TM, Cheng JJ, Eskandar EN. Mechanisms of deep brain stimulation. J Neurophysiol 2016;115(1):19-38.PubMedCrossRef

105.

Little S, Pogosyan A, Neal S, et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol 2013;74(3):449-457.PubMedPubMedCentralCrossRef

106.

Swann NC, de Hemptinne C, Thompson MC, et al. Adaptive deep brain stimulation for Parkinson’s disease using motor cortex sensing. J Neural Eng 2018;15(4):046006.PubMedPubMedCentralCrossRef

107.

Malekmohammadi M, Herron J, Velisar A, et al. Kinematic adaptive deep brain stimulation for resting tremor in Parkinson’s disease. Mov Disord 2016;31(3):426-428.PubMedCrossRef

108.

Temel Y, Visser-Vandewalle V, Kaplan S, Kozan R, Daemen MA, Blokland A, et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res 2006;1120(1):100-105.PubMedCrossRef

109.

Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996;8(7):1408-1414.PubMedCrossRef

110.

Hacker ML, DeLong MR, Turchan M, et al. Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology 2018;91(5):e463-e471.PubMedPubMedCentralCrossRef

111.

Walters H, Shah BB. Focused Ultrasound and other lesioning therapies in movement disorders. Curr Neurol Neurosci Rep 2019;19(9):66.PubMedCrossRef

112.

Jourdain VA, Schechtmann G. Health economics and surgical treatment for Parkinson’s disease in a world perspective: results from an international survey. Stereotact Funct Neurosurg 2014;92(2):71-79.PubMedCrossRef

113.

Hariz MI, Hariz GM. Therapeutic stimulation versus ablation. Handb Clin Neurol 2013;116:63-71.PubMedCrossRef

114.

Krack P, Martinez-Fernandez R, Del Alamo M, Obeso JA. Current applications and limitations of surgical treatments for movement disorders. Mov Disord 2017;32(1):36-52.PubMedCrossRef

115.

Intemann PM, Masterman D, Subramanian I, et al. Staged bilateral pallidotomy for treatment of Parkinson disease. J Neurosurg 2001;94(3):437-44.PubMedCrossRef

116.

Junque C, Alegret M, Nobbe FA, et al. Cognitive and behavioral changes after unilateral posteroventral pallidotomy: relationship with lesional data from MRI. Mov Disord 1999;14(5):780-789.PubMedCrossRef

117.

Lozano AM, Lang AE. Pallidotomy for Parkinson’s disease. Neurosurg Clin N Am 1998;9(2):325-336.PubMedCrossRef

118.

Matsumoto K, Shichijo F, Fukami T. Long-term follow-up review of cases of Parkinson’s disease after unilateral or bilateral thalamotomy. J Neurosurg 1984;60(5):1033-1044.PubMedCrossRef

119.

Merello M, Starkstein S, Nouzeilles MI, Kuzis G, Leiguarda R. Bilateral pallidotomy for treatment of Parkinson’s disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 2001;71(5):611-614.PubMedPubMedCentralCrossRef

120.

Louw DF, Burchiel KJ. Ablative therapy for movement disorders. Complications in the treatment of movement disorders. Neurosurg Clin N Am 1998;9(2):367-373.PubMedCrossRef

121.

Kim R, Alterman R, Kelly PJ, et al. Efficacy of bilateral pallidotomy. Neurosurg Focus 1997;2(3):e8.PubMedCrossRef

122.

Khabarova EA, Denisova NP, Dmitriev AB, Slavin KV, Verhagen Metman L. Deep Brain Stimulation of the Subthalamic Nucleus in Patients with Parkinson Disease with Prior Pallidotomy or Thalamotomy. Brain Sci. 2018 Apr 16;8(4):66. https://doi.org/10.3390/brainsci8040066. PMID: 29659494; PMCID: PMC5924402.

123.

Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord 2006;21(8):1252-1254.PubMedCrossRef

124.

Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson’s disease. Mov Disord 2001;16(1):72-78.PubMedCrossRef

125.

Barlas O, Hanagasi HA, Imer M, Sahin HA, Sencer S, Emre M. Do unilateral ablative lesions of the subthalamic nucleu in parkinsonian patients lead to hemiballism? Mov Disord 2001;16(2):306-310.PubMedCrossRef

126.

Patel NK, Heywood P, O'Sullivan K, McCarter R, Love S, Gill SS. Unilateral subthalamotomy in the treatment of Parkinson’s disease. Brain 2003;126(Pt 5):1136-1145.PubMedCrossRef

127.

Martínez-Fernández R, Rodríguez-Rojas R, Del Álamo M, et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson’s disease: a pilot study. Lancet Neurol 2018;17(1):54-63.CrossRefPubMed

128.

Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson’s disease patients. J Neurosurg 1991;75(5):723-730.PubMedCrossRef

129.

Nagaseki Y, Shibazaki T, Hirai T, et al. Long-term follow-up results of selective VIM-thalamotomy. J Neurosurg 1986;65(3):296-302.PubMedCrossRef

130.

Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery 1995;37(4):680-687.PubMedCrossRef

131.

Kelly PJ, Gillingham FJ. The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson’s disease: a 10-year follow-up study. J Neurosurg 1980;53(3):332-337.PubMedCrossRef

132.

Dallapiazza RF, Lee DJ, De Vloo P, et al. Outcomes from stereotactic surgery for essential tremor. J Neurol Neurosurg Psychiatry 2019;90(4):474-482.PubMedCrossRef

133.

Baron MS, Vitek JL, Bakay RA, Green J, et al. Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996;40(3):355-366.PubMedCrossRef

134.

Fine J, Duff J, Chen R, et al. Long-term follow-up of unilateral pallidotomy in advanced Parkinson’s disease. N Engl J Med 2000;342(23):1708-1714.PubMedCrossRef

135.

Kishore A, Turnbull IM, Snow BJ, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson’s disease. Six-month follow-up with additional 1-year observations. Brain 1997;120 ( Pt 5):729-737.PubMedCrossRef

136.

Hariz MI, Bergenheim AT. A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease. J Neurosurg 2001;94(4):552-558.PubMedCrossRef

137.

Samuel M, Caputo E, Brooks D, Schrag A, et al. A study of medial pallidotomy for Parkinson’s disease: clinical outcome, MRI location and complications. Brain J Neurol 1998;121(1):59-75.CrossRef

138.

Lombardi WJ, Gross RE, Trepanier LL, Lang AE, Lozano AM, Saint-Cyr JA. Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson’s disease: support for the existence of cognitive circuits in the human pallidum. Brain 2000;123 ( Pt 4):746-758.PubMedCrossRef

139.

Saint-Cyr J, Trépanier L, Lang A, Lozano A. Neuropsychological outcome of posteroventral pallidotomy in parkinsonian patients. Mov Disord 1996;11(suppl 1):161.

140.

Soukup VM, Ingram F, Schiess MC, Bonnen JG, Nauta HJ, Calverley JR. Cognitive sequelae of unilateral posteroventral pallidotomy. Arch Neurol 1997;54(8):947-950.PubMedCrossRef

141.

Cosman E. Radiofrequency lesions. Textbook of stereotactic and functional neurosurgery 1996.

142.

Duma CM. Movement disorder radiosurgery—planning, physics and complication avoidance, Prog Neurol Surg 2007;20:249-66.PubMedCrossRef

143.

Young RF, Jacques S, Mark R, et al. Gamma knife thalamotomy for treatment of tremor: long-term results. J Neurosurg 2000;93 Suppl 3:128-35.PubMedCrossRef

144.

Duma CM, Jacques DB, Kopyov OV, Mark RJ, Copcutt B, Farokhi HK. Gamma knife radiosurgery for thalamotomy in parkinsonian tremor: a five-year experience. J Neurosurg 1998;88(6):1044-9.PubMedCrossRef

145.

Franzini A, Moosa S, Prada F, Elias WJ. Ultrasound ablation in neurosurgery: current clinical applications and future perspectives. Neurosurgery 2020;87(1):1-10.PubMedCrossRef

146.

Bond AE, Shah BB, Huss DS, et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol 2017;74(12):1412-1418.PubMedPubMedCentralCrossRef

147.

Schlesinger I, Eran A, Sinai A, et al. MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease. Parkinsons Dis. 2015;2015:219149. https://doi.org/10.1155/2015/219149

148.

Zaaroor M, Sinai A, Goldsher D, Eran A, Nassar M, Schlesinger I. Magnetic resonance–guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. J Neurosurg 2017;128(1):202-210.PubMedCrossRef

149.

Jung NY, Park CK, Kim M, Lee PH, Sohn YH, Chang JW. The efficacy and limits of magnetic resonance–guided focused ultrasound pallidotomy for Parkinson’s disease: a phase I clinical trial. J Neurosurg 2018;130(6):1853-1861.CrossRef

150.

Na YC, Chang WS, Jung HH, Kweon EJ, Chang JW. Unilateral magnetic resonance-guided focused ultrasound pallidotomy for Parkinson disease. Neurology 2015;85(6):549-51.CrossRefPubMed

151.

Magara A, Buhler R, Moser D, Kowalski M, Pourtehrani P, Jeanmonod D. First experience with MR-guided focused ultrasound in the treatment of Parkinson’s disease. J Ther Ultrasound 2014;2:11.PubMedPubMedCentralCrossRef

Titel: Surgical Treatment of Parkinson’s Disease: Devices and Lesion Approaches
verfasst von: Vibhash D. Sharma
Margi Patel
Svjetlana Miocinovic
Publikationsdatum: 01.10.2020
Verlag: Springer International Publishing
Erschienen in: Neurotherapeutics / Ausgabe 4/2020
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-020-00939-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy

Update on the Treatment of Ataxia: Medication and Emerging Therapies

Approach to Cognitive Impairment in Parkinson’s Disease

Sleep Issues in Parkinson’s Disease and Their Management

Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice